만성 B형간염 면역관용기의 정의 및 치료

다국어 초록 (Multilingual Abstract)

In the natural course of chronic hepatitis B, the immune tolerance phase is characterized by HBeAg positivity, very high levels of HBV DNA, and persistent normal alanine aminotransferase. The international guideline recommendation for patients in this phase is observation without antiviral treatment because of the low risk of disease progression and the lack of effective antiviral agents.
However, recent retrospective studies have shown that progression to hepatic fibrosis and hepatocellular carcinoma may occur in patients who are in the immune tolerance phase. Despite the conceptual definition and clinical diagnostic criteria for this phase, it is difficult to accurately diagnose the true immune tolerance phase. Therefore, we should pay attention to the clinical evaluation and interpretation of the immune tolerance phase and understand the clinical situations in which antiviral treatments should be considered.

참고문헌 (Reference)

1 Terrault NA, "Update on prevention, diagnosis, and treatment of chronic hepatitis B : AASLD 2018hepatitis B guidance" 67 : 1560-1599, 2018

2 Wong GL, "Update of liver fibrosis and steatosis with transient elastography(Fibroscan)" 1 : 19-26, 2013

3 Shim JJ, "Serum alanine aminotransferase level and liver-related mortality in patients with chronic hepatitis B : a large national cohort study" 38 : 1751-1759, 2018

4 Young-Sun Lee ; Ha Seok Lee ; Ji Hoon Kim ; Sung Won Chang ; Myung Han Hyun ; Haein Bak ; Sehwa Kim ; Min-jin Lee ; Chan Uk Lee ; Young Kul Jung ; Yeon Seok Seo ; Hyung Joon Yim ; Jong Eun Yeon ; Soon Ho Um ; Kwan Soo Byun, "Role of tenofovir disoproxil fumarate in prevention of perinatal transmission of hepatitis B virus from mother to child: a systematic review and metaanalysis" 대한내과학회 36 (36): 76-85, 2021

5 Kennedy PTF, "Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B" 143 : 637-645, 2012

6 Chon YE, "Performance of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B : a meta-analysis" 7 : e44930-, 2012

7 Chang Y, "Nucleos(t)ide analogue treatment for patients with hepatitis B virus(HBV)e antigen-positive chronic HBV genotype C infection : a nationwide, multicenter, retrospective study" 216 : 1407-1414, 2017

8 Hui CK, "Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase" 46 : 395-401, 2007

9 Wen WH, "Mother-to-infant transmission of hepatitis B virus infection : significance of maternal viral load and strategies for intervention" 59 : 24-30, 2013

10 Korean Association for the Study of the Liver (KASL), "KASL clinical practice guidelines for management of chronic hepatitis B" 대한간학회 25 (25): 93-159, 2019

11 Kim GA, "High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B" 67 : 945-952, 2018

12 Park JY, "High prevalence of significant histology in asymptomatic chronic hepatitis B patients with genotype C and high serum HBV DNA levels" 15 : 615-621, 2008

13 Wong VW, "Four-year outcomes after cessation of tenofovir in immune-tolerant chronic hepatitis B patients" 52 : 347-352, 2018

14 Liu CP, "Factors associated with mother-to-child transmission of hepatitis B virus despite immunoprophylaxis" 54 : 711-716, 2015

15 Vallet-Pichard A, "FIB-4 : an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest" 46 : 32-36, 2007

16 Lee HA, "Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase" 52 : 196-204, 2020

17 Chan HL, "Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA" 146 : 1240-1248, 2014

18 European Association for the Study of the Liver, "EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection" 67 : 370-398, 2017

19 Kim HL, "Cost-effectiveness of antiviral treatment in adult patients with immune-tolerant phase chronic hepatitis B" 70 : 2172-2182, 2021

20 Rosenthal P, "Combination of entecavir/peginterferon Alfa-2a in children with hepatitis B e antigen-positive immune tolerant chronic hepatitis B virus infection" 69 : 2326-2337, 2019

21 Wong GL, "Clinical factors associated with liver stiffness in hepatitis B e antigen-positive chronic hepatitis B patients" 7 : 227-233, 2009

22 Sarin SK, "Asian-Pacific clinical practice guidelines on the management of hepatitis B : a 2015 update" 10 : 1-98, 2016

23 Wai CT, "A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C" 38 : 518-526, 2003

24 신동현 ; 이정훈 ; 김경아 ; 안중현 ; 이지현 ; 김정희 ; 이동현 ; 윤정환 ; 강원석 ; 곽금연 ; 백용한 ; 최문석 ; 이준혁 ; 조광철 ; 백승운, "A Novel Model for Predicting Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B and Normal Alanine Aminotransferase Levels" 거트앤리버 소화기연관학회협의회 11 (11): 528-534, 2017